Sangamo Therapeutics Inc Revenue Growth Rates (SGMO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sangamo Therapeutics Inc   (NASDAQ: SGMO)
 

SGMO's Revenue Growth by Quarter and Year

Sangamo Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SGMO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 1.44
FY 1.44

SGMOs Annual Revenue
Sangamo Therapeutics Inc 's Revenue in the fiscal year 2025 $ 39.55 millions
Sangamo Therapeutics Inc 's Revenue in the fiscal year 2024 $ 57.80 millions
Sangamo Therapeutics Inc 's Revenue in the fiscal year 2023 $ 176.23 millions
Sangamo Therapeutics Inc 's Revenue in the fiscal year 2022 $ 111.30 millions
Sangamo Therapeutics Inc 's Revenue in the fiscal year 2021 $ 110.70 millions




SGMO Revenue first quarter 2026 Y/Y Growth Comment
Sangamo Therapeutics Inc reported drop in Revenue in the first quarter 2026 by -77.61% to $ 1.44 millions, from the same quarter in 2025.
The fall in the first quarter 2026 Sangamo Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 40.43%.

Looking into first quarter 2026 results within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Revenue growth. While Sangamo Therapeutics Inc ' s Revenue meltdown of -77.61% ranks overall at the positon no. 1138 in the first quarter 2026.


SGMO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 88.48 % 270.1 % -92.51 %
3rd Quarter September - -98.83 % 425.64 % -64.47 %
2nd Quarter June - 4986.11 % -94.74 % -76.72 %
1st Quarter March -77.61 % 1241.67 % -99.7 % 459.55 %
FY   - -31.56 % -67.2 % -

Financial Statements
Sangamo Therapeutics Inc 's first quarter 2026 Revenue $ 1.44 millions SGMO's Income Statement
Sangamo Therapeutics Inc 's first quarter 2025 Revenue $ 6.44 millions Quarterly SGMO's Income Statement


SGMO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 2353.45 % -84.72 % -78.3 %
3rd Quarter September - -96.83 % 13625 % 37.43 %
2nd Quarter June - 184.32 % -25 % -95.67 %
1st Quarter March -89.87 % -14.7 % -76.47 % 480.1 %
FY (Year on Year)   - -31.56 % -67.2 % -


Back to SGMO Growth rate Comparisons >> Back to SGMO Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #211
Overall #1138

Revenue Y/Y Growth Statistics
High Average Low
565.52 % 40.43 % -94.38 %
(Jun 30 2025)   (Jun 30 2024)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #211
Overall #1138
Revenue Y/Y Growth Statistics
High Average Low
565.52 % 40.43 % -94.38 %
(Jun 30 2025)   (Jun 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Sangamo Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
13779.78 % 314.19 % -96.83 %
(Sep 30 2024)  


SGMO's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Sangamo Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -89.87% to $ 1.44 millions, from $ 14.23 millions achived in the previous reporting period.

But that's not important problem, as Sangamo Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Revenue quarter on quarter growth. While Sangamo Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3226.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #504
Overall #3226
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #504
Overall #3226
Revenue Q/Q Growth Statistics
High Average Low
13779.78 % 314.19 % -96.83 %
(Sep 30 2024)  


SGMO's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Sangamo Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -89.87% to $ 1.44 millions, from $ 14.23 millions achived in the previous reporting period.

But that's not important problem, as Sangamo Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Revenue quarter on quarter growth. While Sangamo Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3226.


Sangamo Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 34.56 $ 39.55 $ 32.88 $ 81.71 $ 63.76
Y / Y Revenue Growth (TTM) -45.8 % -31.57 % -37.13 % 565.52 % 239.92 %
Year on Year Revenue Growth Overall Ranking # 57 # 3034 # 3163 # 2847 # 2481
Seqeuential Revenue Change (TTM) -12.63 % 20.31 % -59.76 % 28.15 % 10.3 %
Seq. Revenue Growth (TTM) Overall Ranking # 1138 # 1087 # 13 # 2708 # 2813


Cumulative Revenue growth Comment
Sangamo Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -45.8% year on year, at Mar 31 2026 compare to the -31.57% decrease at Dec 31 2025. If the Sangamo Therapeutics Inc 's fiscal year would end at Mar 31 2026, annual Revenue would be $35 millions.

Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 57, from total ranking in previous quarter at 3034.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 23
Overall # 57

Revenue TTM Y/Y Growth Statistics
High Average Low
565.52 %
 40.43 %
-94.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 211
S&P 500 # 1138
Cumulative Revenue growth Comment
Sangamo Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -45.8% year on year, at Mar 31 2026 compare to the -31.57% decrease at Dec 31 2025. If the Sangamo Therapeutics Inc 's fiscal year would end at Mar 31 2026, annual Revenue would be $35 millions.

Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 57, from total ranking in previous quarter at 3034.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 23
Overall # 57

Revenue TTM Y/Y Growth Statistics
High Average Low
565.52 %
40.43 %
-94.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 211
S&P 500 # 1138




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SGMO's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Sangamo Therapeutics Inc Revenue Growth Rates (SGMO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sangamo Therapeutics Inc (CIK 1001233).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-035067
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sangamo Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.